Skip to content
Catalyst

PapersPMID:41565787

Evaluating the antioxidant and anti-inflammatory effect of melatonin in pediatric hemodialysis patients: a randomized, placebo-controlled trial.

Scientific reports2026The record ↗

  1. Finding, moderate evidenceno difference foundMalondialdehyde (circulating)

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →
  • “Also, the MLT group demonstrated marginal reduction in MDA compared to placebo group (F = 3.046, p = 0.092, partial η2 = 0.095), revealing a trend towards decreased oxidative stress that did not reach statistical significance.”
    Study
    RCT
    Duration
    3 months
    Dose studied
    5 mg oral melatonin once daily 1 h before bedtime for 12 weeks
    Population
    children on chronic haemodialysis; primary endpoint, ANCOVA adjusted for baseline MDA and antihypertensive use; serum MDA by ELISA

Study record

Design
randomised controlled trial
Species
human
Population
40 pediatric hemodialysis patients aged 6-18 years
Participants
40
Comparator
placebo
Duration
84 days
Endpoints measured
6